Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Epidermal Growth Factor Receptor Gene Mutation”

273 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 273 results

Not applicableEnded earlyNCT02483416
What this trial is testing

Evaluation of the Impact of Nurse-led Telephone on Treatment Compliance

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 30
Early research (Phase 1)Study completedNCT00903734
What this trial is testing

An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

Who this might be right for
Advanced Cancers
M.D. Anderson Cancer Center 16
Testing effectiveness (Phase 2)UnknownNCT01714908
What this trial is testing

Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21

Who this might be right for
Non-small Cell Lung Cancer
Jinming Yu 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT06194448
What this trial is testing

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

Who this might be right for
Lung Cancer
AstraZeneca 76
Early research (Phase 1)Study completedNCT04959981
What this trial is testing

Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

Who this might be right for
Advanced Non-squamous Non-small-cell Lung Cancer
Erasca, Inc. 24
Not applicableStudy completedNCT03562819
What this trial is testing

Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer).

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
AstraZeneca 268
Not applicableStudy completedNCT02991274
What this trial is testing

ARTEMIS DIANE T790M (An Amino Acid Substitution at Position 790 in EGFR, From a Threonine (T) to a Methionine (M)) Mutation at Hospital Laboratories in Comparison With Central Laboratory

Who this might be right for
Locally Advanced or Metastatic EGFR(+) NSCLC Patients
AstraZeneca 897
Large-scale testing (Phase 3)Active Not RecruitingNCT04351555
What this trial is testing

Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 358
Testing effectiveness (Phase 2)UnknownNCT03062800
What this trial is testing

Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)

Who this might be right for
Advanced Nsclc
Qilu Hospital of Shandong University 232
Not applicableUnknownNCT01697163
What this trial is testing

De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

Who this might be right for
NSCLC
Severance Hospital 155
Testing effectiveness (Phase 2)Looking for participantsNCT06071013
What this trial is testing

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Who this might be right for
Non-small Cell Lung CancerEGFR Gene MutationEGFR-TKI Resistant Mutation
China Medical University Hospital 20
Early research (Phase 1)Looking for participantsNCT04085315
What this trial is testing

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Who this might be right for
Lung Cancer MetastaticEGFR Gene Mutation
Collin Blakely 38
Testing effectiveness (Phase 2)UnknownNCT04470076
What this trial is testing

Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation

Who this might be right for
Non Small Cell Lung CancerSurgeryEGFR Activating Mutation+2 more
Fifth Affiliated Hospital, Sun Yat-Sen University 30
Testing effectiveness (Phase 2)Looking for participantsNCT06300424
What this trial is testing

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

Who this might be right for
Non Small Cell Lung CancerEGFR Gene Mutation
Guangdong Provincial People's Hospital 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06018688
What this trial is testing

Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.

Who this might be right for
Non Small Cell Lung CancerEGFR Gene Mutation
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 44
Not applicableUnknownNCT06095934
What this trial is testing

Efficacy and Safety of Neoantigen Peptide Vaccine in the Treatment of Advanced NSCLC Progressed After EGFR-TKI Treatment

Who this might be right for
NSCLCEGFR Gene Mutation
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 20
Not applicableLooking for participantsNCT06304441
What this trial is testing

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Who this might be right for
Leptomeningeal Metastasis
Guangzhou Medical University 100
Early research (Phase 1)Ended earlyNCT05153408
What this trial is testing

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Who this might be right for
Lung NeoplasmCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+24 more
Blueprint Medicines Corporation 20
Not applicableUnknownNCT06207292
What this trial is testing

Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer

Who this might be right for
NSCLCNSCLC Stage IVOligometastatic Disease+9 more
Radiotherapy Oncology Centre "Santa Maria" Hospital 100
Large-scale testing (Phase 3)Looking for participantsNCT06970639
What this trial is testing

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

Who this might be right for
NSCLC Patients With Brain Metastasis
Allist Pharmaceuticals, Inc. 380
Load More Results